Patents by Inventor Christopher David Beadle

Christopher David Beadle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3,4-dihydroisoquinolin-2(1)-yl compounds
    Patent number: 8962654
    Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: February 24, 2015
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, David Andrew Coates, Junliang Hao, Joseph Herman Krushinski, Jr., Matthew Robert Reinhard, John Mehnert Schaus, Craig Daniel Wolfangel
  • 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS
    Publication number: 20140357664
    Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
    Type: Application
    Filed: May 27, 2014
    Publication date: December 4, 2014
    Applicant: Eli Lilly and Company
    Inventors: Christopher David BEADLE, David Andrew COATES, Junliang HAO, Joseph Herman KRUSHINSKI, JR., Matthew Robert REINHARD, John Mehnert SCHAUS, Craig Daniel WOLFANGEL
  • MGlu 2/3 agonists
    Patent number: 8575214
    Abstract: The present invention provides novel mGlu2/3 agonists of the formula wherein R1, R2, and R3 are as defined herein, for use in the treatment of neurological or psychiatric disorders.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 5, 2013
    Assignee: Eli Lilly and Company
    Inventors: Stephen Richard Baker, Christopher David Beadle, Barry Peter Clark, James Allen Monn, Lourdes Prieto
  • 3-Aminopyrrolidines as inhibitors of monoamine uptake
    Patent number: 7619096
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: November 17, 2009
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, Manuel Javier Cases-Thomas, Barry Peter Clark, Peter Thaddeus Gallagher, John Joseph Masters, Graham Henry Timms, Magnus Wilhelm Walter, Maria Ann Whatton, Virginia Ann Wood, Jeremy Gilmore
  • 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
    Patent number: 7432280
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: October 7, 2008
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, Manuel Javier Cases-Thomas, Barry Peter Clark, Peter Thaddeus Gallagher, John Joseph Masters, Graham Henry Timms, Magnus Wilhelm Walter, Maria Ann Whatton, Virginia Ann Wood, Jeremy Gilmore